BioNexus Gene Lab CorpBGLCEarnings & Financial Report
Nasdaq
NextApr 29, 2026
BGLC Q3 2025 Key Financial Metrics
Revenue
$2.5M
Gross Profit
$377.7K
Operating Profit
$-702.5K
Net Profit
$-709.0K
Gross Margin
14.8%
Operating Margin
-27.6%
Net Margin
-27.9%
YoY Growth
-3.3%
EPS
$-0.40
Financial Flow
BioNexus Gene Lab Corp Q3 2025 Financial Summary
BioNexus Gene Lab Corp reported revenue of $2.5M for Q3 2025, with a net profit of $-709.0K (-27.9% margin). Cost of goods sold was $2.2M, operating expenses totaled $1.1M.
Key Financial Metrics
| Total Revenue | $2.5M |
|---|---|
| Net Profit | $-709.0K |
| Gross Margin | 14.8% |
| Operating Margin | -27.6% |
| Report Period | Q3 2025 |
BioNexus Gene Lab Corp Annual Revenue by Year
BioNexus Gene Lab Corp annual revenue history includes year-by-year totals (for example, 2024 revenue was $9.5M).
| Year | Annual Revenue |
|---|---|
| 2024 | $9.5M |
| 2023 | $9.8M |
| 2022 | $10.9M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.3M | $2.4M | $2.0M | $2.6M | $2.5M | $2.1M | $2.3M | $2.5M |
| YoY Growth | -20.0% | 0.2% | -23.1% | 3.0% | 11.0% | -10.3% | 14.5% | -3.3% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $11.4M | $11.2M | $11.1M | $11.0M | $10.4M | $9.5M | $9.4M | $7.6M |
| Liabilities | $1.7M | $1.8M | $1.6M | $1.6M | $2.1M | $1.7M | $1.9M | $804966 |
| Equity | $9.7M | $9.3M | $9.5M | $9.4M | $8.3M | $7.8M | $7.5M | $6.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-261909 | $-34442 | $-670540 | $-1.5M | $-69771 | $-824072 | $-737907 | $-1.2M |